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Purpose of the study
To study if the risk of primary pulmonary hypertension
(PPH) has changed in the last 10 years, we estimated the
incidence of PPH in HIV infection in France and we inves-
tigated its risk factors.
Methods
The French Hospital Database on HIV (FHDH-ANRS
CO4) which started in 1992 in 62 hospitals in France and
enrolled HIV-seropositive subjects followed in hospitals
offered this opportunity. We used a Poisson regression
model to identify factors associated with the rate of PPH
among patients enrolled in the FHDH since 1996, the year
of the advent of combination antiretroviral therapy
(cART), including protease inhibitors (PIs). Multivariable
analysis included variables with p < 0.20 in univariable
analyses, that is gender, age, transmission group, and
updated CD4 cell counts, AIDS diagnosis and antiretrovi-
ral treatment.
Summary of results
During the period 1996 to June 2006, among the 73,291
subjects included in the study, PPH was diagnosed in 203
patients during a median follow-up of 64 months.
Women, who account for 31% of the HIV-infected popu-
lation, have 1.7 times the risk of men to present a PPH
during their follow-up (95% CI = 1.2–2.2) and PPH is
more often diagnosed among IVDUs who present a 3.7
higher risk than other transmission group (95% CI = 2.8–
4.9). The sex standardized incidence of PPH in the HIV-
infected population (81.9 per 100,000 PY in 1996–1998,
138.8 in 1999–2001, 108.7 in 2002–2004 and 68.3 in
2005–2006) is higher that in the general population (0.16
per 100,000 PY) in Europe. No impact of antiretroviral
treatment on PPH occurrence was found. AIDS diagnosis
and low CD4 cell count during the follow-up were found
as independent predictors of PPH occurrence with
increasing incidence from 37.8 per 100,000 PY for
patients with CD4 cell count ≥500/mm3 to 225.6 for
patients with CD4 cell count<50/mm3.
Conclusion
Our results are consistent with the assumption that the
HIV is a risk factor of PPH occurrence, and that PPH is
related to a high degree of immunosupression. Neverthe-
less, even among patients with more than 500 CD4/mm3,
the risk of PPH is higher than in the general population.
Although PPH may be under-reported in the database,
there is no reason to believe that the rate of under-notifi-
cation varied over time or with risk factors of PPH, there-
fore, the increased risk we observed could be under
estimated in our study, while we are confident in the risk
factors evidenced. Active surveillance for PPH should be
considered for patients with low CD4 cell count and clin-
ical symptoms such as cough.
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